Terms: = Lymphoma AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987
359 results:
1. FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling.
Kanaoka D; Yamada M; Yokoyama H; Nishino S; Kunimura N; Satoyoshi H; Wakabayashi S; Urabe K; Ishii T; Nakanishi M
Cancer Res Commun; 2024 Feb; 4(2):312-327. PubMed ID: 38265263
[TBL] [Abstract] [Full Text] [Related]
2. Exploring Thiazolopyridine AV25R: Unraveling of Biological Activities, Selective Anti-Cancer Properties and In Silico Target and Binding Prediction in Hematological Neoplasms.
Ladwig A; Gupta S; Ehlers P; Sekora A; Alammar M; Koczan D; Wolkenhauer O; Junghanss C; Langer P; Murua Escobar H
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138609
[TBL] [Abstract] [Full Text] [Related]
3. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
4. A GPX4 non-enzymatic domain and mdm2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis induction.
Niu F; Yang R; Feng H; Liu Y; Liu R; Ma B
Biochem Biophys Res Commun; 2023 Dec; 684():149125. PubMed ID: 37897912
[TBL] [Abstract] [Full Text] [Related]
5. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
Johansson KB; Zimmerman MS; Dmytrenko IV; Gao F; Link DC
Leukemia; 2023 Dec; 37(12):2356-2366. PubMed ID: 37838759
[TBL] [Abstract] [Full Text] [Related]
6. Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction.
Gasparoli L; Virely C; Tsakaneli A; Che N; Edwards D; Bartram J; Hubank M; Pal D; Heidenreich O; Martens JHA; De Boer J; Williams O
Haematologica; 2024 Apr; 109(4):1069-1081. PubMed ID: 37794795
[TBL] [Abstract] [Full Text] [Related]
7. Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma.
Forberg AL; Unrau J; Weber KS; Rutz AC; Lund S; Guidinger J; Pelzel A; Hauge J; Hemmen AJ; Hartert KT
Ann Hematol; 2024 Jan; 103(1):199-209. PubMed ID: 37792064
[TBL] [Abstract] [Full Text] [Related]
8. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.
Liu X; Duan Y; Wang G; Zhu P
Diagn Pathol; 2023 Sep; 18(1):105. PubMed ID: 37735390
[TBL] [Abstract] [Full Text] [Related]
9. Higher 13-Gene-Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T-Cell lymphoma Patients.
Chen C; Huang L; Chen Z; Ou Q; Liu S; Jiang X; Chen F; Wei X; Guo H; Shao Y; Zeng C; Li Y; Li W
Adv Biol (Weinh); 2023 Dec; 7(12):e2300042. PubMed ID: 37658484
[TBL] [Abstract] [Full Text] [Related]
10. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma.
Xie H; Xu W; Liang J; Liu Y; Zhuo C; Zou X; Luo W; Xiao J; Lin Y; Chen L; Li H
Bioorg Chem; 2023 Nov; 140():106762. PubMed ID: 37572533
[TBL] [Abstract] [Full Text] [Related]
11. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
Ishikawa C; Mori N
Med Oncol; 2023 May; 40(6):172. PubMed ID: 37165174
[TBL] [Abstract] [Full Text] [Related]
12. Synthesis and biological evaluation of dual mdm2/XIAP inhibitors based on the tetrahydroquinoline scaffold.
Albadari N; Xie Y; Liu T; Wang R; Gu L; Zhou M; Wu Z; Li W
Eur J Med Chem; 2023 Jul; 255():115423. PubMed ID: 37130471
[TBL] [Abstract] [Full Text] [Related]
13. A First-in-Human Phase I Study of Milademetan, an mdm2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or lymphomas.
Gounder MM; Bauer TM; Schwartz GK; Weise AM; LoRusso P; Kumar P; Tao B; Hong Y; Patel P; Lu Y; Lesegretain A; Tirunagaru VG; Xu F; Doebele RC; Hong DS
J Clin Oncol; 2023 Mar; 41(9):1714-1724. PubMed ID: 36669146
[TBL] [Abstract] [Full Text] [Related]
14. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
Tucker ER; Jiménez I; Chen L; Bellini A; Gorrini C; Calton E; Gao Q; Che H; Poon E; Jamin Y; Martins Da Costa B; Barker K; Shrestha S; Hutchinson JC; Dhariwal S; Goodman A; Del Nery E; Gestraud P; Bhalshankar J; Iddir Y; Saberi-Ansari E; Saint-Charles A; Geoerger B; Marques Da Costa ME; Pierre-Eugène C; Janoueix-Lerosey I; Decaudin D; Nemati F; Carcaboso AM; Surdez D; Delattre O; George SL; Chesler L; Tweddle DA; Schleiermacher G
Clin Cancer Res; 2023 Apr; 29(7):1317-1331. PubMed ID: 36602782
[TBL] [Abstract] [Full Text] [Related]
15. The risk of cancer in patients with primary Sjögren syndrome: a single-center study from Turkey.
Aslan B; Öğüt TS; Erbasan F; Dilbil M; Çelik E; Terzioğlu ME; Yazısız V
Turk J Med Sci; 2022 Jun; 52(3):587-595. PubMed ID: 36326315
[TBL] [Abstract] [Full Text] [Related]
16. Stilbene B10 induces apoptosis and tumor suppression in lymphoid Raji cells by BTK-mediated regulation of the KRAS/HDAC1/EP300/PEBP1 axis.
Varier KM; Dan G; Liu W; Wu G; Xiao C; Lei H; Ling T; Jiang Y; Chen Y; Ben-David Y; Li Y; Zhang N; Gajendran B; Shen X
Biomed Pharmacother; 2022 Dec; 156():113887. PubMed ID: 36274467
[TBL] [Abstract] [Full Text] [Related]
17. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
[TBL] [Abstract] [Full Text] [Related]
18. Druggable host gene dependencies in primary effusion lymphoma.
Kuehnle N; Gottwein E
Curr Opin Virol; 2022 Oct; 56():101270. PubMed ID: 36182745
[TBL] [Abstract] [Full Text] [Related]
19. Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography-tandem mass spectrometry.
Kagan AB; Anders NM; Hemingway A; Lee EQ; Kelly KR; Lee HC; Xu-Welliver M; Piekarz R; Rudek MA
Biomed Chromatogr; 2022 Nov; 36(11):e5467. PubMed ID: 35895384
[TBL] [Abstract] [Full Text] [Related]
20. IDO1 plays a tumor-promoting role via mdm2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma.
Sun C; Li M; Zhang L; Sun F; Chen H; Xu Y; Lan Y; Zhang L; Lu S; Zhu J; Huang J; Wang J; Hu Y; Feng Y; Zhang Y
Cell Death Dis; 2022 Jun; 13(6):572. PubMed ID: 35760783
[TBL] [Abstract] [Full Text] [Related]
[Next]
